Foresite Capital Management III’s Akari Therapeutics AKTX Stock Holding History

Foresite Capital Management III’s Portfolio AKTX Stock Details AKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-246	Closed	-$1.39M	–	26
2016 Q4	$1.39M	Hold	246	–	–	0.6%	16
2016 Q3	$1.68M	Hold	246	–	–	0.78%	12
2016 Q2	$2.66M	Sell	246 -84	-25%	-$1.08M	1.82%	13
2016 Q1	$3.69M	Hold	330	–	–	2.86%	13
2015 Q4	$3.83M	Buy	+330	New	+$4.9M	3.39%	14

Other funds holding AKTX

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Foresite Capital Management III's AKTX Position: Q1 2017 in Review

Foresite Capital Management III sold out of Akari Therapeutics (AKTX) in Q1 2017, closing a stake of 246 shares — an estimated $1.39M sold.

Foresite Capital Management III first reported a position in AKTX in Q4 2015 and held it in 5 quarters. The position peaked at $3.83M in Q4 2015. 11 funds tracked by Wall St. Rank hold AKTX as of Q1 2017.

Foresite Capital Management III reported no remaining Akari Therapeutics position as of Q1 2017 after selling out during the quarter.
Foresite Capital Management III sold 246 Akari Therapeutics shares in Q1 2017, an estimated $1.39M.
Foresite Capital Management III first reported a position in Akari Therapeutics in Q4 2015 and held it in 5 quarters.
Foresite Capital Management III's Akari Therapeutics position peaked at $3.83M in Q4 2015.
11 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2017.

Based on Foresite Capital Management III's 13F filing for Q1 2017, filed 12 May 2017.